BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Katz MH, Merchant NB, Brower S, Branda M, Posner MC, William Traverso L, Abrams RA, Picozzi VJ, Pisters PW; American College of Surgeons Oncology Group. Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: results from the ACOSOG Z5031 trial. Ann Surg Oncol. 2011;18:337-344. [PMID: 20811779 DOI: 10.1245/s10434-010-1282-y] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 Rau BM. Preparing for prospective clinical trials: a national initiative of an excellence registry for consecutive pancreatic cancer resections. World J Surg 2014;38:463-4. [PMID: 24240676 DOI: 10.1007/s00268-013-2357-2] [Reference Citation Analysis]
2 Katz MHG, Wang H, Balachandran A, Bhosale P, Crane CH, Wang X, Pisters PWT, Lee JE, Vauthey J, Abdalla EK, Wolff R, Abbruzzese J, Varadhachary G, Chopin-laly X, Charnsangavej C, Fleming JB. Effect of Neoadjuvant Chemoradiation and Surgical Technique on Recurrence of Localized Pancreatic Cancer. J Gastrointest Surg 2012;16:68-79. [DOI: 10.1007/s11605-011-1748-7] [Cited by in Crossref: 79] [Cited by in F6Publishing: 69] [Article Influence: 7.2] [Reference Citation Analysis]
3 Katz MHG, Francescatti AB, Hunt KK; Cancer Surgery Standards Program of the American College of Surgeons. Technical Standards for Cancer Surgery: Commission on Cancer Standards 5.3–5.8. Ann Surg Oncol. [DOI: 10.1245/s10434-022-11375-w] [Reference Citation Analysis]
4 Katz MHG, Wolff R, Crane CH, Varadhachary G, Javle M, Lin E, Evans DB, Lee JE, Fleming JB, Pisters PWT. Survival and Quality of Life of Patients with Resected Pancreatic Adenocarcinoma Treated with Adjuvant Interferon-Based Chemoradiation: A Phase II Trial. Ann Surg Oncol 2011;18:3615-22. [DOI: 10.1245/s10434-011-1847-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
5 Osipov A, Nissen N, Rutgers J, Dhall D, Naziri J, Chopra S, Li Q, Hendifar AE, Tuli R. Redefining the Positive Margin in Pancreatic Cancer: Impact on Patterns of Failure, Long-Term Survival and Adjuvant Therapy. Ann Surg Oncol 2017;24:3674-82. [PMID: 28871564 DOI: 10.1245/s10434-017-6076-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
6 Hoffe S, Rao N, Shridhar R. Neoadjuvant vs adjuvant therapy for resectable pancreatic cancer: the evolving role of radiation. Semin Radiat Oncol 2014;24:113-25. [PMID: 24635868 DOI: 10.1016/j.semradonc.2013.11.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
7 Liles JS, Katz MH. Pancreaticoduodenectomy with vascular resection for pancreatic head adenocarcinoma. Expert Rev Anticancer Ther. 2014;14:919-929. [PMID: 24833085 DOI: 10.1586/14737140.2014.919860] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
8 Bonaroti JW, Doane S, McCue PA, Winter JM. Intraoperative Frozen Section Analysis of the Pancreas: A Case Report and Review of the Literature. Case Rep Pancreat Cancer 2016;2:71-4. [PMID: 30631821 DOI: 10.1089/crpc.2016.0014] [Reference Citation Analysis]
9 Merkow RP, Bilimoria KY, Bentrem DJ, Pitt HA, Winchester DP, Posner MC, Ko CY, Pawlik TM. National Assessment of Margin Status as a Quality Indicator after Pancreatic Cancer Surgery. Ann Surg Oncol 2014;21:1067-74. [DOI: 10.1245/s10434-013-3338-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
10 Ethun CG, Kooby DA. The importance of surgical margins in pancreatic cancer. J Surg Oncol. 2016;113:283-288. [PMID: 26603829 DOI: 10.1002/jso.24092] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 5.1] [Reference Citation Analysis]
11 Swan RZ, Lau KN, Sindram D, Iannitti DA, Martinie JB. Pancreatic Resection in a Large Tertiary Care Community-Based Hospital: Building a Successful Pancreatic Surgery Program. Surgical Oncology Clinics of North America 2011;20:487-500. [DOI: 10.1016/j.soc.2011.01.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
12 Kang CM, Hwang HK, Choi SH, Lee WJ. Controversial issues of neoadjuvant treatment in borderline resectable pancreatic cancer. Surg Oncol. 2013;22:123-131. [PMID: 23518243 DOI: 10.1016/j.suronc.2013.02.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
13 Katz MH, Pisters PW, Lee JE, Fleming JB. Borderline resectable pancreatic cancer: what have we learned and where do we go from here? Ann Surg Oncol 2011;18:608-10. [PMID: 21136179 DOI: 10.1245/s10434-010-1460-y] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
14 Evans DB, Wolff RA. Adjuvant Therapy for Pancreatic Cancer: A Logical Strategy in Search of Progress. Ann Surg Oncol 2011;18:1224-8. [DOI: 10.1245/s10434-011-1633-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
15 Katz MH, Lee JE, Pisters PW, Skoracki R, Tamm E, Fleming JB. Retroperitoneal dissection in patients with borderline resectable pancreatic cancer: operative principles and techniques. J Am Coll Surg 2012;215:e11-8. [PMID: 22818108 DOI: 10.1016/j.jamcollsurg.2012.05.015] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 4.3] [Reference Citation Analysis]
16 Delpero JR, Boher JM, Sauvanet A, Le Treut YP, Sa-Cunha A, Mabrut JY, Chiche L, Turrini O, Bachellier P, Paye F. Pancreatic adenocarcinoma with venous involvement: is up-front synchronous portal-superior mesenteric vein resection still justified? Ann Surg Oncol. 2015;22:1874-1883. [PMID: 25665947 DOI: 10.1245/s10434-014-4304-3] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 9.1] [Reference Citation Analysis]
17 Delpero JR, Bachellier P, Regenet N, Le Treut YP, Paye F, Carrere N, Sauvanet A, Autret A, Turrini O, Monges-Ranchin G. Pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a French multicentre prospective evaluation of resection margins in 150 evaluable specimens. HPB (Oxford). 2014;16:20-33. [PMID: 23464850 DOI: 10.1111/hpb.12061] [Cited by in Crossref: 105] [Cited by in F6Publishing: 94] [Article Influence: 11.7] [Reference Citation Analysis]
18 Fong ZV, Tan WP, Lavu H, Kennedy EP, Mitchell DG, Koniaris LG, Sauter PK, Rosato EL, Yeo CJ, Winter JM. Preoperative imaging for resectable periampullary cancer: clinicopathologic implications of reported radiographic findings. J Gastrointest Surg 2013;17:1098-106. [PMID: 23553385 DOI: 10.1007/s11605-013-2181-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
19 Prakash LR, Wang H, Zhao J, Nogueras-Gonzalez GM, Cloyd JM, Tzeng CD, Kim MP, Lee JE, Katz MHG. Significance of Cancer Cells at the Vein Edge in Patients with Pancreatic Adenocarcinoma Following Pancreatectomy with Vein Resection. J Gastrointest Surg 2020;24:368-79. [PMID: 30820801 DOI: 10.1007/s11605-019-04126-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
20 Bal M, Rane S, Talole S, Ramadwar M, Deodhar K, Patil P, Goel M, Shrikhande S. Tumour origin and R1 rates in pancreatic resections: towards consilience in pathology reporting. Virchows Arch 2018;473:293-303. [PMID: 30091124 DOI: 10.1007/s00428-018-2429-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
21 Ikoma N, Kim MP, Tzeng CD, Tran Cao HS, Lee JE, Katz MH. External Retraction Technique for Robotic Pancreatoduodenectomy. Journal of the American College of Surgeons 2020;231:e8-e10. [DOI: 10.1016/j.jamcollsurg.2020.06.025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
22 Rocha FG, Hashimoto Y, Traverso LW, Dorer R, Kozarek R, Helton WS, Picozzi VJ. Interferon-based Adjuvant Chemoradiation for Resected Pancreatic Head Cancer: Long-term Follow-up of the Virginia Mason Protocol. Annals of Surgery 2016;263:376-84. [DOI: 10.1097/sla.0000000000001190] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
23 Arango NP, Prakash LR, Chiang Y, Dewhurst WL, Bruno ML, Ikoma N, Kim MP, Lee JE, Katz MH, Tzeng CD. Risk-Stratified Pancreatectomy Clinical Pathway Implementation and Delayed Gastric Emptying. J Gastrointest Surg 2021;25:2221-30. [DOI: 10.1007/s11605-020-04877-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 McIntyre CA, Winter JM. Diagnostic evaluation and staging of pancreatic ductal adenocarcinoma. Semin Oncol 2015;42:19-27. [PMID: 25726049 DOI: 10.1053/j.seminoncol.2014.12.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
25 Rivoire M, Dupré A. [Is the surgeon still the main prognosis factor?]. Bull Cancer 2013;100:973-81. [PMID: 24103859 DOI: 10.1684/bdc.2013.1828] [Reference Citation Analysis]
26 Wang J, Estrella JS, Peng L, Rashid A, Varadhachary GR, Wang H, Lee JE, Pisters PW, Vauthey JN, Katz MH, Gomez HF, Evans DB, Abbruzzese JL, Fleming JB, Wang H. Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation. Cancer 2012;118:3801-11. [PMID: 22180096 DOI: 10.1002/cncr.26717] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 4.5] [Reference Citation Analysis]
27 Kang MJ, Kim SW. Current status and perspectives of the future of pancreatic surgery: Establishment of evidence by integration of "art" and "science". Ann Gastroenterol Surg 2021;5:738-46. [PMID: 34755005 DOI: 10.1002/ags3.12494] [Reference Citation Analysis]
28 Katz MH, Shi Q, Ahmad SA, Herman JM, Marsh Rde W, Collisson E, Schwartz L, Frankel W, Martin R, Conway W, Truty M, Kindler H, Lowy AM, Bekaii-Saab T, Philip P, Talamonti M, Cardin D, LoConte N, Shen P, Hoffman JP, Venook AP. Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101. JAMA Surg. 2016;151:e161137. [PMID: 27275632 DOI: 10.1001/jamasurg.2016.1137] [Cited by in Crossref: 225] [Cited by in F6Publishing: 197] [Article Influence: 37.5] [Reference Citation Analysis]
29 Andrén-Sandberg A. Pancreatic cancer: chemotherapy and radiotherapy. N Am J Med Sci 2011;3:1-12. [PMID: 22540056 DOI: 10.4297/najms.2011.31] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
30 Cooper AB, Tzeng CW, Katz MH. Treatment of borderline resectable pancreatic cancer. Curr Treat Options Oncol. 2013;14:293-310. [PMID: 23793524 DOI: 10.1007/s11864-013-0244-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
31 Westgaard A, Clausen OPF, Gladhaug IP. Survival estimates after pancreatoduodenectomy skewed by non-standardized histopathology reports: STANDARDIZED HISTOPATHOLOGICAL EVALUATION. APMIS 2011;119:689-700. [DOI: 10.1111/j.1600-0463.2011.02783.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
32 Verbeke CS, Gladhaug IP. Dissection of Pancreatic Resection Specimens. Surg Pathol Clin 2016;9:523-38. [PMID: 27926357 DOI: 10.1016/j.path.2016.05.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
33 Kooby DA, Lad NL, Squires MH, Maithel SK, Sarmiento JM, Staley CA, Adsay NV, El-Rayes BF, Weber SM, Winslow ER, Cho CS, Zavala KA, Bentrem DJ, Knab M, Ahmad SA, Abbott DE, Sutton JM, Kim HJ, Yeh JJ, Aufforth R, Scoggins CR, Martin RC, Parikh AA, Robinson J, Hashim YM, Fields RC, Hawkins WG, Merchant NB. Value of intraoperative neck margin analysis during Whipple for pancreatic adenocarcinoma: a multicenter analysis of 1399 patients. Ann Surg. 2014;260:494-501; discussion 501-3. [PMID: 25115425 DOI: 10.1097/sla.0000000000000890] [Cited by in Crossref: 66] [Cited by in F6Publishing: 22] [Article Influence: 9.4] [Reference Citation Analysis]
34 Schlitter AM, Häberle L, Richter C, Huss R, Esposito I. [Standardized diagnosis of pancreatic head carcinoma]. Pathologe 2021;42:453-63. [PMID: 34357472 DOI: 10.1007/s00292-021-00971-4] [Reference Citation Analysis]
35 Epstein JD, Kozak G, Fong ZV, He J, Javed AA, Joneja U, Jiang W, Ferrone CR, Lillemoe KD, Cameron JL, Weiss MJ, Lavu H, Yeo CJ, Fernandez-Del Castillo C, Wolfgang CL, Winter JM. Microscopic lymphovascular invasion is an independent predictor of survival in resected pancreatic ductal adenocarcinoma. J Surg Oncol 2017;116:658-64. [PMID: 28628722 DOI: 10.1002/jso.24723] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
36 Maksymov V, Hogan M, Khalifa MA. An anatomical-based mapping analysis of the pancreaticoduodenectomy retroperitoneal margin highlights the urgent need for standardized assessment. HPB (Oxford) 2013;15:218-23. [PMID: 23374362 DOI: 10.1111/j.1477-2574.2012.00561.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
37 Rahman SH, Urquhart R, Molinari M. Neoadjuvant therapy for resectable pancreatic cancer. World J Gastrointest Oncol 2017; 9(12): 457-465 [PMID: 29290916 DOI: 10.4251/wjgo.v9.i12.457] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
38 Delpero JR, Jeune F, Bachellier P, Regenet N, Le Treut YP, Paye F, Carrere N, Sauvanet A, Adham M, Autret A, Poizat F, Turrini O, Boher JM. Prognostic Value of Resection Margin Involvement After Pancreaticoduodenectomy for Ductal Adenocarcinoma: Updates From a French Prospective Multicenter Study. Annals of Surgery 2017;266:787-96. [DOI: 10.1097/sla.0000000000002432] [Cited by in Crossref: 48] [Cited by in F6Publishing: 18] [Article Influence: 9.6] [Reference Citation Analysis]
39 Alemi F, Alseidi A, Scott Helton W, Rocha FG. Multidisciplinary management of locally advanced pancreatic ductal adenocarcinoma. Curr Probl Surg 2015;52:362-98. [PMID: 26363649 DOI: 10.1067/j.cpsurg.2015.07.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
40 Gómez-mateo MC, Sabater-ortí L, Ruiz-montesinos I, Ferrández-izquierdo A. Pathology Reporting of Resected Pancreatic/Periampullary Cancer Specimen. In: Tewari M, editor. Surgery for Pancreatic and Periampullary Cancer. Singapore: Springer; 2018. pp. 247-80. [DOI: 10.1007/978-981-10-7464-6_26] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
41 Eng OS, Goswami J, Moore D, Chen C, Brumbaugh J, Gannon CJ, August DA, Carpizo DR. Safety and efficacy of LigaSure usage in pancreaticoduodenectomy. HPB (Oxford) 2013;15:747-52. [PMID: 23782268 DOI: 10.1111/hpb.12116] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
42 Snyder RA, Ahmad S, Katz MHG. Pancreas cancer trials for early stage disease: Surgeons leading therapeutic cooperative group trials. J Surg Oncol 2021. [PMID: 34586635 DOI: 10.1002/jso.26701] [Reference Citation Analysis]
43 Merchant NB, Parikh AA, Liu EH. Adjuvant chemoradiation therapy for pancreas cancer: who really benefits? Adv Surg 2010;44:149-64. [PMID: 20919520 DOI: 10.1016/j.yasu.2010.05.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
44 Katz MH, Fleming JB, Lee JE, Pisters PW. Current status of adjuvant therapy for pancreatic cancer. Oncologist. 2010;15:1205-1213. [PMID: 21045189 DOI: 10.1634/theoncologist.2010-0121] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
45 Petrucciani N, Nigri G, Debs T, Giannini G, Sborlini E, Antolino L, Aurello P, D'angelo F, Gugenheim J, Ramacciato G. Frozen section analysis of the pancreatic margin during pancreaticoduodenectomy for cancer: Does extending the resection to obtain a secondary R0 provide a survival benefit? Results of a systematic review. Pancreatology 2016;16:1037-43. [DOI: 10.1016/j.pan.2016.09.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
46 Gaskill CE, Maxwell J, Ikoma N, Kim MP, Tzeng CW, Lee JE, Katz MHG. History of preoperative therapy for pancreatic cancer and the MD Anderson experience. J Surg Oncol 2021;123:1414-22. [PMID: 33831256 DOI: 10.1002/jso.26394] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
47 Denbo JW, Fleming JB. Definition and Management of Borderline Resectable Pancreatic Cancer. Surg Clin North Am 2016;96:1337-50. [PMID: 27865281 DOI: 10.1016/j.suc.2016.07.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
48 Enane FO, Saunthararajah Y, Korc M. Differentiation therapy and the mechanisms that terminate cancer cell proliferation without harming normal cells. Cell Death Dis. 2018;9:912. [PMID: 30190481 DOI: 10.1038/s41419-018-0919-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
49 Schwarz L, Katz MH. Diagnosis and Management of Borderline Resectable Pancreatic Adenocarcinoma. Hematol Oncol Clin North Am 2015;29:727-40. [PMID: 26226907 DOI: 10.1016/j.hoc.2015.04.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
50 Grossberg AJ, Chu LC, Deig CR, Fishman EK, Hwang WL, Maitra A, Marks DL, Mehta A, Nabavizadeh N, Simeone DM, Weekes CD, Thomas CR Jr. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. CA Cancer J Clin 2020;70:375-403. [PMID: 32683683 DOI: 10.3322/caac.21626] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 12.5] [Reference Citation Analysis]
51 Katz MH, Marsh R, Herman JM, Shi Q, Collison E, Venook AP, Kindler HL, Alberts SR, Philip P, Lowy AM. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol. 2013;20:2787-2795. [PMID: 23435609 DOI: 10.1245/s10434-013-2886-9] [Cited by in Crossref: 215] [Cited by in F6Publishing: 179] [Article Influence: 23.9] [Reference Citation Analysis]
52 Isidro ML, Lugo G, Fidalgo O, García-Arias S. Adequacy of pathology reports of specimens from patients with differentiated thyroid cancer. Endocr Pathol 2012;23:215-20. [PMID: 23152121 DOI: 10.1007/s12022-012-9226-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
53 Fonseca AL, Fleming JB. Surgery for pancreatic cancer: critical radiologic findings for clinical decision making. Abdom Radiol 2018;43:374-82. [DOI: 10.1007/s00261-017-1332-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
54 Esposito I, Konukiewitz B, Schlitter AM, Klöppel G. Pathology of pancreatic ductal adenocarcinoma: Facts, challenges and future developments. World J Gastroenterol 2014; 20(38): 13833-13841 [PMID: 25320520 DOI: 10.3748/wjg.v20.i38.13833] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 32] [Article Influence: 5.5] [Reference Citation Analysis]
55 Rau BM, Moritz K, Schuschan S, Alsfasser G, Prall F, Klar E. R1 resection in pancreatic cancer has significant impact on long-term outcome in standardized pathology modified for routine use. Surgery. 2012;152:S103-S111. [PMID: 22766366 DOI: 10.1016/j.surg.2012.05.015] [Cited by in Crossref: 94] [Cited by in F6Publishing: 86] [Article Influence: 9.4] [Reference Citation Analysis]